484 related articles for article (PubMed ID: 26351025)
21. Maternal treatment of spontaneously hypertensive rats with pentaerythritol tetranitrate reduces blood pressure in female offspring.
Wu Z; Siuda D; Xia N; Reifenberg G; Daiber A; Münzel T; Förstermann U; Li H
Hypertension; 2015 Jan; 65(1):232-7. PubMed ID: 25385760
[TBL] [Abstract][Full Text] [Related]
22. Unexpected, tolerance-devoid vasomotor and platelet actions of pentaerythrityl tetranitrate.
Fink B; Bassenge E
J Cardiovasc Pharmacol; 1997 Dec; 30(6):831-6. PubMed ID: 9436825
[TBL] [Abstract][Full Text] [Related]
23. Non-hemodynamic effects of organic nitrates and the distinctive characteristics of pentaerithrityl tetranitrate.
Gori T; Daiber A
Am J Cardiovasc Drugs; 2009; 9(1):7-15. PubMed ID: 19178128
[TBL] [Abstract][Full Text] [Related]
24. Effects of nonintermittent treatment of rabbits with pentaerythritol tetranitrate on vascular reactivity and superoxide production.
Kojda G; Hacker A; Noack E
Eur J Pharmacol; 1998 Aug; 355(1):23-31. PubMed ID: 9754935
[TBL] [Abstract][Full Text] [Related]
25. Sustained beneficial effects of oral pentaerythritol tetranitrate on ventricular function in chronic congestive heart failure.
Shah PK; Shellock FG; Berman DS; Rubin SA; Singh BN; Swan HJ
Nouv Presse Med; 1980 Sep; 9(34 Suppl):2447-50. PubMed ID: 7422534
[TBL] [Abstract][Full Text] [Related]
26. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction.
Smith RS; Agata J; Xia CF; Chao L; Chao J
Life Sci; 2005 Apr; 76(21):2457-71. PubMed ID: 15763077
[TBL] [Abstract][Full Text] [Related]
27. Beneficial effect of pentaerythrityl tetranitrate on functional and morphological changes in the rat thoracic aorta evoked by long-term nitric oxide synthase inhibition.
Török J; Kristek F
Vascul Pharmacol; 2002 Mar; 38(3):177-82. PubMed ID: 12402517
[TBL] [Abstract][Full Text] [Related]
28. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
[TBL] [Abstract][Full Text] [Related]
29. Formation of reactive oxygen species by pentaerithrityltetranitrate and glyceryl trinitrate in vitro and development of nitrate tolerance.
Dikalov S; Fink B; Skatchkov M; Stalleicken D; Bassenge E
J Pharmacol Exp Ther; 1998 Aug; 286(2):938-44. PubMed ID: 9694953
[TBL] [Abstract][Full Text] [Related]
30. Mitochondrial oxidative stress and dysfunction in myocardial remodelling.
Tsutsui H; Kinugawa S; Matsushima S
Cardiovasc Res; 2009 Feb; 81(3):449-56. PubMed ID: 18854381
[TBL] [Abstract][Full Text] [Related]
31. New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance.
Daiber A; Wenzel P; Oelze M; Münzel T
Clin Res Cardiol; 2008 Jan; 97(1):12-20. PubMed ID: 17938848
[TBL] [Abstract][Full Text] [Related]
32. Sustained benefits or oral pentaerythritol tetranitrate on ventricular function in chronic congestive heart failure.
Shellock FG; Shah PK; Berman DS; Rubin SA; Singh BN; Swan HJ
Clin Pharmacol Ther; 1980 Oct; 28(4):436-40. PubMed ID: 7408403
[TBL] [Abstract][Full Text] [Related]
33. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes.
Bitar MS; Wahid S; Mustafa S; Al-Saleh E; Dhaunsi GS; Al-Mulla F
Eur J Pharmacol; 2005 Mar; 511(1):53-64. PubMed ID: 15777779
[TBL] [Abstract][Full Text] [Related]
34. [Atherosclerosis progression and standard in coronary disease. Nitrate with special talents: PETN (pentaerythritol tetranitrate) is vasoprotective].
MMW Fortschr Med; 2002 Nov; 144(45):51. PubMed ID: 12534064
[No Abstract] [Full Text] [Related]
35. Pentaerythrityl tetranitrate attenuates structural changes in conduit arteries evoked by long-term NO-synthase inhibition.
Kristek F
Br J Pharmacol; 2000 May; 130(2):450-6. PubMed ID: 10807685
[TBL] [Abstract][Full Text] [Related]
36. In vivo effects of pentaerythrityl-tetranitrate and isosorbide-5-mononitrate on the development of atherosclerosis and endothelial dysfunction in cholesterol-fed rabbits.
Kojda G; Stein D; Kottenberg E; Schnaith EM; Noack E
J Cardiovasc Pharmacol; 1995 May; 25(5):763-73. PubMed ID: 7543171
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study.
Jurt U; Gori T; Ravandi A; Babaei S; Zeman P; Parker JD
J Am Coll Cardiol; 2001 Sep; 38(3):854-9. PubMed ID: 11527645
[TBL] [Abstract][Full Text] [Related]
38. Practical prevention of cardiac remodeling and atrial fibrillation with full-spectrum antioxidant therapy and ancillary strategies.
McCarty MF
Med Hypotheses; 2010 Aug; 75(2):141-7. PubMed ID: 20083360
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological induction of vascular extracellular superoxide dismutase expression in vivo.
Oppermann M; Balz V; Adams V; Dao VT; Bas M; Suvorava T; Kojda G
J Cell Mol Med; 2009 Jul; 13(7):1271-8. PubMed ID: 19320775
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of TGF-beta1 signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through angiogenesis and reduction of apoptosis.
Chen LL; Yin H; Huang J
Cardiovasc Pathol; 2007; 16(4):221-30. PubMed ID: 17637430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
